Search Results

Alaya.bio, an in vivo gene delivery biotech company, announces the acquisition of all assets previously owned by Ixaka France, a preclinical-stage immunotherapy biotech company specializing in in vivo CAR T-cell therapy.

Ixaka Ltd, an integrated cell and gene therapy company focused on boosting the natural power of the body to cure disease, announces the appointment of Dr Karen Miller as Chief Scientific Officer.

Ixaka Ltd, an integrated cell and gene therapy company focused on the natural power of the body to cure disease, announces the appointment of Nick Robbins-Cherry as Chief Financial Officer and board Director, and George O’Rourke as Vice President and General Manager of Ixaka France.

Ixaka Ltd and SomaLogic announce a research collaboration to support the development of aptamer-based bispecific therapeutics.

Ixaka Ltd, an integrated cell and gene therapy company focused on the natural power of the body to cure disease, announces that Christian Hoyer Millar has joined the Company’s Board as a Non-Executive Director.

Ixaka Ltd, an integrated cell and gene therapy company focused on the natural power of the body to cure disease

Ixaka Ltd, an integrated cell and gene therapy company, announces positive interim results of its lead REX-001 drug candidate from a Phase 3 clinical trial, which evaluated the safety and efficacy results 12 months after treatment with REX-001 or placebo in patients diagnosed with chronic limb-threatening ischemia and diabetes.

Ixaka Ltd, an integrated cell and gene therapy company, announces that Dr Cecile Bauche, Chief Scientific Officer, will present its in vivo gene delivery platform and the key bioproduction challenges associated with advancing an in vivo CAR-T therapy into the clinic at the 6th CAR TCR Summit on Tuesday, 31 August, 2021 at 2.30pm ET / 11.30am PT.

Ixaka Ltd, an integrated cell and gene therapy company, announces that Advanced Therapy Medicinal Product classification has been granted by the European Medicines Agency for its Chemically Encapsulated Lentiviral vector for Targeted In Vivo CAR T-cell therapy targeted nanoparticle product.

Italfarmaco is making headway against DMD as it announced positive results from a Phase III study, Clover’s homologous booster against Omicron increases antibodies, and much more.